With three pledges on patient data that are important for medical research
GlaxoSmithKline has announced it will open up anonymised data from clinical trials for further research. Shar Nebhrajani argues that openness can lead to more innovation, and asks: is it time for new models of intellectual property rights?
Yesterday we gave evidence to the Caldicott information governance review - about the importance of safely sharing patient data for research.
At AMRC, one of the things we regularly tell the government and other stakeholders is how keen patients are to be involved in research. At the last count 72% of the public told us they would like their doctor to offer them the chance to be involved in clinical trials. And yet apparently up to […]
Medical research organisations, including AMRC, have supported a joint statement outlining how the EU's plans to update data protection law may impact on the use of patient data for health research and recommending a few issues the government should raise when discussing the changes in Europe.
With the details of almost every person in the UK, the health records held by the NHS are an invaluable resource for researchers. George Osborne reiterated the value of data in his autumn statement, highlighting it as a driver of growth through research and innovation and David Cameron spoke of it today. With this in […]